MPOX : Un nouveau décès à Madagascar et fin de l’épidémie aux Comores – Le Journal De Mayotte

Madagascar recorded a new Mpox fatality and the Comoros declared the end of its Mpox epidemic on June 12, 2026, according to reporting from Le Journal De Mayotte. These updates reflect contrasting public health trajectories for the virus within the Indian Ocean region.

The reported death in Madagascar marks a continuation of the virus’s presence in the country. Le Journal De Mayotte reported the fatality on June 12, 2026, though specific patient demographics and the clinical timeline leading to the death were not detailed in the report.

Simultaneously, health authorities in the Comoros have officially closed their current outbreak. The declaration indicates that the Comoros has met the necessary epidemiological criteria to consider the epidemic over, according to the same source.

Why did the Comoros end its Mpox epidemic?

The Comoros ended its Mpox epidemic after meeting specific public health benchmarks. While Le Journal De Mayotte did not list the exact case numbers, the World Health Organization (WHO) typically requires a period of two incubation cycles with zero new cases before an outbreak is declared over.

This outcome contrasts with the situation in Madagascar. The presence of a new death suggests that Madagascar continues to struggle with community transmission or the management of severe cases.

The differing results between these two neighboring island nations highlight how local surveillance and response speeds affect outbreak duration. The Comoros’ success suggests effective containment, while Madagascar’s recent fatality indicates a persistent public health threat.

What are the current risks of Mpox in the region?

Mpox is a viral zoonosis caused by the monkeypox virus, a member of the Orthopoxvirus genus. According to the WHO, the virus spreads through close contact with infected people, animals, or contaminated materials.

The risk in the Indian Ocean region is compounded by the existence of different virus clades. Clade I is historically associated with more severe disease and higher fatality rates than Clade II, which was responsible for the global outbreak in 2022.

Madagascar’s recent fatality aligns with the higher severity risks associated with Clade I strains often found in Central and West Africa. Public health agencies monitor these strains closely because they can lead to more frequent complications in immunocompromised individuals.

How is Mpox identified and managed?

Health professionals identify Mpox through a combination of clinical observation and laboratory testing. Common symptoms include a characteristic rash, fever, and swollen lymph nodes, according to the Centers for Disease Control and Prevention (CDC).

Management of the virus focuses on supportive care and isolation to prevent further spread. In severe cases, antiviral treatments such as tecovirimat may be used, though availability varies by region.

Vaccination remains a primary tool for prevention. The WHO recommends targeted vaccination for high-risk groups and those with known exposure to the virus to reduce the likelihood of infection and death.

What happens next for regional surveillance?

The end of the epidemic in the Comoros does not eliminate the risk of reintroduction. Health officials must maintain surveillance to detect new cases arriving via travel or trade.

For Madagascar, the recent death necessitates a review of current containment strategies. The country’s health ministry faces the challenge of identifying the source of the infection and preventing a wider surge in cases.

Regional cooperation through the Africa CDC is critical. The agency coordinates the sharing of genomic sequencing data to track which clade is circulating in the Indian Ocean, as this determines the effectiveness of available vaccines and the expected severity of the disease.